Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCMC Markets Regulatory News (CMCX)

Share Price Information for CMC Markets (CMCX)

Share Price is delayed by 15 minutes
Get Live Data
457.00    -8.00 (-1.72%)
Bid:
454.50
Ask:
455.00
Spread: 0.50 (0.11%)
Market Cap: £1.25b
CMCX Live PriceLast checked at - London Stock Exchange

Intraday CMC Markets Share Chart

H1 2022 Pre-Close Trading Update

7 Oct 2021 07:00

RNS Number : 2660O
CMC Markets Plc
07 October 2021
 

7 October 2021

CMC Markets Plc

 

H1 2022 Pre-Close Trading Update

For the six months ended 30 September 2021

 

Reiterating FY guidance; increased relative contribution from the non-leveraged business continues

CMC Markets Plc ("CMC" or "the Group"), a leading global provider of online trading and institutional ("B2B") platform technology solutions, today issues a trading update for the six months to 30 September 2021 ("H1 2022" or "the period").

 

Key Highlights

 

· H1 2022 net operating income expected to be approximately £126 million. FY 2022 net operating income guidance reiterated at £250-280 million.

· H1 2022 leveraged gross client income is expected to be approximately £127 million (H1 2021: £174 million).

· H1 2022 leveraged net trading revenue is expected to be approximately £100 million (H1 2021: £200 million).

· H1 2022 non-leveraged net trading revenue is expected to be approximately £24 million (H1 2021: £26 million) representing 19% of Group net operating income versus 11% in H1 2021.

· Announced the acquisition of over 500,000 share investing clients of Australia and New Zealand Banking Group Limited ("ANZ"), with total assets in excess of AUD$45 billion which is due to complete in the next 12-18 months.

 

 

Trading Update

CMC reiterates prior guidance and expects FY 2022 net operating income to settle in a range between £250-280 million. Overall client AUM remains near record levels. H1 2022 active clients are moderately lower compared to H1 2021, nevertheless the monthly trading client numbers continue to remain at similar levels to those reported earlier in the year. Increased market activity exiting September led to improved client trading volumes. 

H1 2022 leveraged net trading revenue is expected to be approximately £100 million (H1 2021: £200 million). The Group's non-leveraged net trading revenue is expected to be approximately £24 million for H1 2022 (H1 2021: £26 million). In H1 our Australian stockbroking business experienced the highest AUM on record and finished the period with the highest number of monthly active clients for the year to date. H1 2022 non-leveraged net trading revenue is expected to represent some 19% of total Group net operating income, marking a new high for CMC.

During September 2021 CMC announced the acquisition of over 500,000 Share Investing clients from ANZ, bringing to an end the existing white label partnership. Ownership of these clients will continue to support multi-year growth in the region and remains core to our non-leveraged growth strategy.

 

Operating costs for H1 2022, excluding variable remuneration, are expected to be approximately £84 million (H1 2021: £79 million). As already highlighted, this is primarily a result of the Group's continued investment in technology which has resulted in higher personnel costs.

 

The results for the six months ended 30 September 2021 will be announced on 17 November 2021.

 

 

Lord Cruddas, Chief Executive Officer, commented:

"We closed the first six months with a pickup in market volatility and client trading volumes following what was a more subdued environment from the start of the year. More importantly the big event for the company was the acquisition of the ANZ stockbroking clients. This transaction, when completed (over a 12-18 month period), will boost our non-leveraged business with over 500,000 investing clients with total assets in excess of AUD$45bn. Our non-leveraged business continues to offer the greatest growth potential and now represents approximately 50 per cent of our business in Australia and near 20 per cent of the business overall. This is the highest proportional level since we launched our non-leveraged platforms. This is even before we integrate the ANZ transaction. We are on a fast track to diversification, using our existing platform technology to win B2B and B2C non-leveraged business. This will be further boosted with the launch of our new UK investment platform, which will offer both B2C and B2B potential. We look forward to updating you more in our H1 results on 17th November 2021".

 

Enquiries

CMC Markets Plc

James Cartwright, Investor Relations investor.relations@cmcmarkets.com

Euan Marshall, Chief Financial Officer

 

Camarco +44 (0) 20 3757 4994

Geoffrey Pelham-Lane

Ed Gascoigne-Pees

Jennifer Renwick

 

Notes to Editors

 

CMC Markets Plc ("CMC"), whose shares are listed on the London Stock Exchange under the ticker CMCX (LEI: 213800VB75KAZBFH5U07), was established in 1989 and is now one of the world's leading online financial trading businesses. The Group serves retail and institutional clients through regulated offices and branches in 12 countries, with a significant presence in the UK, Australia, Germany and Singapore. CMC offers an award-winning, online and mobile trading platform, enabling clients to trade up to 10,000 financial instruments across shares, indices, foreign currencies, commodities and treasuries through contracts for difference ("CFDs"), financial spread bets (in the UK and Ireland only) and, in Australia, access stockbroking services. More information is available at http://www.cmcmarkets.com/group/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUPGGGUUPGGQQ
Date   Source Headline
9th Jun 202610:49 amRNSDirector/PDMR Shareholding
4th Jun 20267:05 amRNSDirectorate change
4th Jun 20267:00 amRNSPreliminary Results
6th May 20264:45 pmRNSDirector/PDMR Shareholding
8th Apr 20263:49 pmRNSDirector/PDMR Shareholding
24th Mar 202610:00 amRNSDirectorate change
6th Mar 20263:54 pmRNSDirector/PDMR Shareholding
6th Feb 20263:57 pmRNSDirector/PDMR Shareholding
12th Jan 202612:16 pmRNSDirector/PDMR Shareholding
6th Jan 20261:38 pmRNSDirector/PDMR Shareholding
8th Dec 20252:22 pmRNSDirector/PDMR Shareholding
20th Nov 20257:10 amRNSDividend Declaration
20th Nov 20257:00 amRNSInterim Results
6th Nov 20254:55 pmRNSDirector/PDMR Shareholding
3rd Nov 20251:30 pmRNSDirectorate change
7th Oct 20254:02 pmRNSDirector/PDMR Shareholding
29th Sep 20257:00 amRNSWestpac and CMC Extend Strategic Relationship
11th Sep 20259:40 amRNSDirector/PDMR Shareholding
8th Sep 202511:50 amRNSDirector/PDMR Shareholding
5th Sep 202512:14 pmRNSAppointment of Senior Independent Director
19th Aug 20254:22 pmRNSDirector/PDMR Shareholding
19th Aug 20254:20 pmRNSDirector/PDMR Shareholding
7th Aug 20253:59 pmRNSHolding(s) in Company
6th Aug 20254:08 pmRNSDirector/PDMR Shareholding
4th Aug 20251:23 pmRNSDirector/PDMR Shareholding
31st Jul 20253:53 pmRNSDirector/PDMR Shareholding
24th Jul 20251:21 pmRNSResult of AGM
23rd Jul 20255:20 pmRNSDirector/PDMR Shareholding
18th Jul 20252:36 pmRNSDirector/PDMR Shareholding
16th Jul 20254:57 pmRNSDirector/PDMR Shareholding
8th Jul 20253:04 pmRNSDirector/PDMR Shareholding
20th Jun 20255:11 pmRNSNotice of AGM
19th Jun 20254:53 pmRNSDirector/PDMR Shareholding
18th Jun 202512:18 pmRNSDirector/PDMR Shareholding
12th Jun 20259:45 amRNSConfirmation of Dividend Details
6th Jun 20254:07 pmRNSDirector/PDMR Shareholding
5th Jun 202512:48 pmRNSAnnual Financial Report
5th Jun 20257:30 amRNSDividend Declaration
5th Jun 20257:05 amRNSBoard and Directorate Changes
5th Jun 20257:00 amRNSFinal Results
7th May 20253:35 pmRNSDirector/PDMR Shareholding
8th Apr 20252:10 pmRNSDirector/PDMR Shareholding
7th Mar 20254:48 pmRNSDirector/PDMR Shareholding
6th Mar 202512:21 pmRNSDirector/PDMR Shareholding
27th Feb 20253:25 pmRNSDirector/PDMR Shareholding
25th Feb 20257:00 amRNSDirectorate Change
6th Feb 20253:01 pmRNSDirector/PDMR Shareholding
23rd Jan 20257:00 amRNSTrading Update
13th Jan 202510:08 amRNSDirector/PDMR Shareholding
6th Jan 20254:24 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.